Navigation Links
Vasogen Announces Implementation of Strategic Restructuring Plan
Date:4/14/2008

MISSISSAUGA, ON, April 14 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), today announced that it has implemented a strategic restructuring plan to significantly reduce its cash burn rate and focus its efforts on opportunities that the Board and management believe are most likely to provide long-term shareholder value. This plan re-focuses Vasogen's resources on the development of its VP series of drugs while the Company seeks alternatives to fund further development of the Celacade(TM) System, the Company's technology for the treatment of chronic heart failure. As a result of this restructuring, which reduces Vasogen's work force by approximately 85%, the Company expects to have approximately two years of cash resources.

As previously reported, Vasogen has encountered significant delays with the FDA regarding the design of ACCAIM II, a clinical trial to support an application for U.S. market approval of Celacade for the treatment of patients with NYHA Class II heart failure. Given these delays, Vasogen's current lack of access to capital, and the uncertainty surrounding the FDA's continued opposition to a relatively small trial utilizing a Bayesian statistical design, the Company has placed on hold plans to fund ACCLAIM II. The Company will, however, continue to work with the FDA towards finalizing the design of ACCLAIM II, and will evaluate potential strategic alternatives to fund such a study. In addition, subsequent to the recent receipt of a much lower than anticipated revenue forecast for Celacade from its European marketing partner, Grupo Ferrer, Vasogen plans to discontinue operational and financial support for European commercialization and is exploring alternative strategies with Ferrer. Ferrer's sales forec
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Calif. , Jan. 22. 2015  Varian Medical Systems (NYSE: ... software, has been honored for its commitment to sustainability with ... companies. Varian is the highest ranked healthcare equipment company among ... today during the World Economic Forum at Davos, ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ...
(Date:12/24/2014)... December 23, 2014 On Friday, December ... the Omnibus and Continuing Resolution Appropriations Act of 2015, ... eligible to receive funding through the Congressionally Directed Medical ... (DoD). The Hydrocephalus Association (HA), working in conjunction with ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... SUNNYVALE, Calif., Sept. 15 Advanced Chemical,Transport, one ... announced the opening of a new location in ... its environmental services -- hazardous,biological and radioactive waste ... and environmental health and,safety outsourcing -- from the ...
... China, Sept. 15 3SBio Inc. (Nasdaq:,SSRX), a ... and marketing biopharmaceutical products, today,announced the results of ... of Shareholders held on September 12, 2008 (Friday) ... the Company,s shareholders re-elected Dr. Jing Lou,Liping Xu, ...
... CMS, Inc., an Elekta Company and,worldwide leader ... announced the commercial launch of its new 4D ... Focal product line that also includes FocalSim and,FocalPro, ... the,visualization and utilization of 4D image sets to ...
Cached Biology Technology:Advanced Chemical Transport Opens Merced Facility 2CMS, Inc., an Elekta Company, Announces Commercial Availability of Focal4D(TM) 2
(Date:12/19/2014)... Inc., the leading personal genetics company, today announced the publication ... of individuals from across the United States ... hundred years ago, the United States ... continents. This study illuminates how American history and the ongoing ...
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to current ... enables HITLAB to conduct regulated smart device and smart ... safety and research quality. "HITLAB is determined ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has ... Market 2015-2019" report to their offering. ... is a technology used for the identification of individuals. ... a person such as nose, jaw edges, mouth, and ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... them into adulthood and may render them more susceptible to ... new UBC study. A team led by UBC researchers ... healthy adults aged 25-40 years. Those who participated in ... circumstances related to income, education and occupation during the first ...
... of unicellular marine microorganisms that are not only a crucial ... fossils, which are found in abundance, provide scientists with an ... the history of the earth. Now, planktonic foraminifera ... have given up a secret of their very own. ...
... first time, the Society of Interventional Radiology has assembled ... artery embolization, a treatment directed toward a number of ... may occur due to the presence of uterine fibroids. ... "virtual" collection allows health care providers and the public ...
Cached Biology News:Early-life experience linked to chronic diseases later in life: UBC research 2Surviving mass extinction by leading a double life 2Avoiding hysterectomy: Major interventional radiology E-collection info available 2Avoiding hysterectomy: Major interventional radiology E-collection info available 3
... J. Karn (1995) This ... information and methods for the study of ... cycle; reverse transcriptase, ribonuclease H, integrase and ... RNA binding assays; Tat and Rev assays; ...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Tachykinin (H-2)...
Human GATA-2 Affinity Purified Polyclonal Ab...
Biology Products: